Your browser is no longer supported. Please, upgrade your browser.
Settings
SRRA [NASD]
Sierra Oncology, Inc.
Index- P/E- EPS (ttm)-7.11 Insider Own6.95% Shs Outstand13.67M Perf Week0.78%
Market Cap345.62M Forward P/E- EPS next Y-5.12 Insider Trans1.33% Shs Float3.28M Perf Month16.45%
Income-87.20M PEG- EPS next Q-1.54 Inst Own70.50% Short Float1.43% Perf Quarter14.62%
Sales0.20M P/S1728.12 EPS this Y74.60% Inst Trans19.22% Short Ratio1.07 Perf Half Y31.16%
Book/sh6.95 P/B3.35 EPS next Y26.40% ROA-83.70% Target Price35.80 Perf Year67.07%
Cash/sh6.54 P/C3.56 EPS next 5Y- ROE-92.10% 52W Range13.32 - 24.00 Perf YTD45.29%
Dividend- P/FCF- EPS past 5Y- ROI-66.40% 52W High-2.08% Beta0.86
Dividend %- Quick Ratio11.90 Sales past 5Y- Gross Margin- 52W Low76.43% ATR1.05
Employees69 Current Ratio11.90 Sales Q/Q- Oper. Margin- RSI (14)62.52 Volatility3.72% 4.88%
OptionableNo Debt/Eq0.00 EPS Q/Q-50.80% Profit Margin- Rel Volume1.14 Prev Close23.29
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume43.80K Price23.50
Recom1.50 SMA203.94% SMA507.58% SMA20022.36% Volume25,711 Change0.90%
Sep-27-21Initiated Cantor Fitzgerald Overweight $33
Dec-11-20Resumed H.C. Wainwright Buy $29
Jul-30-20Initiated H.C. Wainwright Buy $20
Dec-06-19Initiated Oppenheimer Outperform $1.20
Oct-23-17Upgrade Jefferies Hold → Buy
Mar-10-17Upgrade SunTrust Hold → Buy
Feb-22-17Resumed Wedbush Outperform $3 → $4
Nov-26-21 05:00AM  
Nov-12-21 07:00AM  
Nov-10-21 04:15PM  
Nov-05-21 07:00AM  
Nov-04-21 09:00AM  
Nov-03-21 04:05PM  
Oct-19-21 02:09PM  
Oct-04-21 04:14PM  
Sep-07-21 07:00AM  
Sep-03-21 04:05PM  
Aug-09-21 07:00AM  
Aug-05-21 04:10PM  
04:05PM  
07:00AM  
Jul-22-21 07:00AM  
Jul-13-21 07:23AM  
Jul-07-21 07:00AM  
Jun-23-21 07:00AM  
07:00AM  
Jun-21-21 07:00AM  
07:00AM  
Jun-14-21 07:00AM  
07:00AM  
Jun-11-21 03:00AM  
Jun-03-21 07:00AM  
07:00AM  
May-25-21 07:00AM  
May-21-21 07:00AM  
07:00AM  
May-19-21 05:00PM  
May-12-21 10:00AM  
May-11-21 09:49AM  
May-07-21 07:00AM  
07:00AM  
Mar-23-21 07:00AM  
07:00AM  
Mar-12-21 04:16AM  
Mar-11-21 07:00AM  
07:00AM  
Mar-05-21 08:00AM  
Mar-03-21 07:00AM  
07:00AM  
Feb-12-21 07:00AM  
07:00AM  
Feb-09-21 07:00AM  
Jan-18-21 08:11AM  
Jan-05-21 07:00AM  
07:00AM  
Dec-15-20 04:27PM  
Dec-11-20 06:49PM  
Dec-07-20 10:00AM  
Dec-05-20 10:30AM  
10:30AM  
Dec-01-20 07:00AM  
07:00AM  
Nov-25-20 07:00AM  
Nov-18-20 02:33AM  
Nov-12-20 07:00AM  
Nov-05-20 08:00AM  
08:00AM  
07:00AM  
Oct-02-20 07:00AM  
07:00AM  
Sep-14-20 07:00AM  
07:00AM  
Sep-04-20 03:47PM  
Aug-06-20 07:05AM  
07:00AM  
Jul-28-20 07:00AM  
Jun-26-20 11:44AM  
Jun-18-20 12:00PM  
Jun-16-20 04:05PM  
Jun-12-20 02:30AM  
02:30AM  
May-27-20 07:00AM  
07:00AM  
May-26-20 07:00AM  
07:00AM  
May-14-20 09:00AM  
May-07-20 08:00AM  
08:00AM  
07:00AM  
May-04-20 12:45PM  
Apr-21-20 05:31PM  
Mar-03-20 07:00AM  
Feb-26-20 08:47AM  
07:00AM  
Feb-25-20 07:00AM  
Feb-11-20 07:23AM  
Feb-06-20 07:00AM  
Jan-28-20 07:09AM  
Jan-22-20 07:00AM  
Jan-06-20 02:17PM  
Dec-19-19 06:08PM  
Dec-07-19 09:00AM  
09:00AM  
Dec-02-19 07:00AM  
Nov-26-19 07:00AM  
Nov-20-19 07:00AM  
Nov-14-19 04:05PM  
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Collard Craig ADirectorNov 24Buy23.097,899182,34813,500Nov 24 07:07 PM
Collard Craig ADirectorNov 23Buy22.955,601128,5155,601Nov 24 07:07 PM
DILLY STEPHEN GEORGECEO and PresidentMay 19Buy17.835,00089,1505,000May 20 06:59 PM